🇺🇸 IDX184 in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 3
Most-reported reactions
- Cholecystitis Acute — 2 reports (66.67%)
- Confusional State — 1 report (33.33%)
Frequently asked questions
Is IDX184 approved in United States?
IDX184 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for IDX184 in United States?
Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.